# A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects

> **NCT04055168** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 24 (actual)

## Conditions studied

- Dyslipidemia

## Interventions

- **DRUG:** AZD6615
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04055168
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-24
- **Primary completion:** 2020-02-10
- **Final completion:** 2020-02-10
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** It was decided to not run the Japanese cohorts in the study.
- **Last updated:** 2020-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04055168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04055168, "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04055168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*